HOME >> MEDICINE >> NEWS
Iressa news backgrounder: Testing of smart drug expands at M. D. Anderson Cancer Center

It is a drug suffused in promise, a next-generation therapy that has shown glimmers of powerful potential. Iressa is the kind of treatment that oncologists dream of - a pill that can be swallowed once a day, a non-toxic therapy that causes few side effects. For 10 percent of patients who have tried it, people who have no other options left for them, Iressa seems to make the difference between life and death. Another 30 percent to 40 percent of patients who have used the drug have a better, if not a longer, life.

But for most patients, Iressa does not shrink their cancer. That fact has become a challenge to researchers at The University of Texas M. D. Anderson Cancer Center. They are dedicated to solving the central puzzle that Iressa, and similar other targeted therapies, pose - what are the cancers that may best respond, and which patients will benefit?

M. D. Anderson researchers have been at the forefront of testing Iressa, as well as a slew of other experimental drugs that target critical cancer cell pathways. They have been involved in all phases of clinical trials looking at the effectiveness of Iressa in common lung cancer, work that helped lead to federal Food and Drug Administration approval of the drug in early 2003 for use when standard therapy has not helped lung cancer patients.

Now, investigators at M. D. Anderson are testing Iressa in malignant brain cancer and are poised to study it in a number of cancers, including head and neck, breast, and prostate, along with further investigations in lung cancer.

"M. D. Anderson is one of the leading institutions in developing targeted therapies such as Iressa," says Frank Fossella, M.D., professor in the Department of Thoracic/Head and Neck Medical Oncology, who has treated many lung and other head and neck cancers where it has shown tantalizing benefit.

"So far, Iressa has been a good news, bad news story. The response rates are not as high as we woul
'"/>

Contact: Laura Sussman
lsussman@mdanderson.org
713-745-2457
University of Texas M. D. Anderson Cancer Center
28-Apr-2004


Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Gene mutations predict which lung cancers will respond to Iressa
2. Iressa news backgrounder
3. Chemoprevention backgrounder: Working for a future of cancer chemoprevention
4. Cancer gene therapy news backgrounder: New ideas fuel next generation gene therapy research
5. Cancer markers news backgrounder: Future of cancer diagnosis, treatment lies in tumor barcode
6. St. Jude scientist to lead NCI Pediatric Preclinical Testing Program
7. Testing drugs ability to reverse stroke after standard three-hour window has closed
8. Testing may one day pinpoint which early-stage cancer patients are at risk for relapse
9. Testing earlier for gestational diabetes a smarter way to screen pregnant women
10. Testing for alcohol problems in the workplace
11. UNC Researchers Testing First In New Class Of AIDS Drugs

Post Your Comments:
(Date:4/21/2015)... BC (PRWEB) April 21, 2015 Angelo’s ... complimentary pick-up and delivery for clients that avail the ... Surrey by Angelo’s is done with hi-tech equipments, making ... for customers. They use all natural, high pressure steam ... well as hand washing for area rugs made with ...
(Date:4/21/2015)... (PRWEB) April 21, 2015 Information is the ... Kevin Ryan, MD, FACP, empowers patients and their families with ... is the Rumor and Cancer is the Answer" and ... and informative language to guide patients from diagnosis through treatment ... patients active participants in their treatment, at home and in ...
(Date:4/21/2015)... New York, NY (PRWEB) April 21, 2015 ... provider of advanced delivery technologies and development solutions ... announced the launch of ADVASEPT™ Lock, a stopper-less, ... efficient delivery of injectable medications. Easily opened, ADVASEPT ... safe, convenient and functional container closure with the ...
(Date:4/21/2015)... WA (PRWEB) April 21, 2015 ... Practice Edition 2 for otolaryngologists, bringing the most ... the healthcare community. Otolaryngologists can now experience ... by a trusted source in the industry, Lyft, ... integration with leading EHRs. , “Lyft is very ...
(Date:4/21/2015)... April 21, 2015 QuickMedical, a ... and supplies, now represents Schiller America's ... ECGs, Stress Tests, and Vital Signs Monitors, among ... Switzerland, is a global leader in the development ... are developed in close cooperation with the world's ...
Breaking Medicine News(10 mins):Health News:Angelo’s FabriClean Now Offers Area Rug Cleaning in South Surrey with Complimentary Pick-Up and Delivery 2Health News:Authoritative guide and new accompanying therapeutic web portal bridge information gaps in cancer treatment 2Health News:Catalent Announces the Expansion of its Advanced, Aseptic, Glass-Free Injectable Platform with New ADVASEPT™ Lock Delivery Technology 2Health News:Lyft Expands Its Offerings to Include Dragon® Medical Practice Edition 2 for Otolaryngologists. 2Health News:QuickMedical Launches New Product Line: Schiller America 2Health News:QuickMedical Launches New Product Line: Schiller America 3
(Date:4/21/2015)... , April 21, 2015 InfuSystem Holdings, ... infusion pumps and related services for the healthcare industry ... Canada , announces today that it ... all of the assets of Ciscura Holding Company, Inc., ... GA , was a privately-held Southeastern regional provider ...
(Date:4/21/2015)... 21, 2015  A new, cutting edge prostate cancer ... promises to revolutionize the way prostate cancer is diagnosed.  ... Montsouris Institute in Paris, France , ... the North Florida / South ... prostate cancer diagnosis and management to Greater ...
(Date:4/21/2015)... 21, 2015 Whitehall-based ... dazzling export-led growth in just 4 years. ... part in winning the Queen,s Award for Enterprise, ... Oxford PharmaGenesis. As part of the world,s first ... bring new medicines to the world in areas ...
Breaking Medicine Technology:InfuSystem Announces Acquisition Of Ciscura's Infusion Pump Fleet 2InfuSystem Announces Acquisition Of Ciscura's Infusion Pump Fleet 3InfuSystem Announces Acquisition Of Ciscura's Infusion Pump Fleet 4Kasraeian Urology Unveils Jacksonville's First UroNav Advanced Prostate Cancer Detection Technology 2Kasraeian Urology Unveils Jacksonville's First UroNav Advanced Prostate Cancer Detection Technology 3Queen's Award Crowns Achievements of Fast-growing London Consultancy 2Queen's Award Crowns Achievements of Fast-growing London Consultancy 3Queen's Award Crowns Achievements of Fast-growing London Consultancy 4Queen's Award Crowns Achievements of Fast-growing London Consultancy 5
Cached News: